PT4070788T - Formulações farmacêuticas - Google Patents

Formulações farmacêuticas

Info

Publication number: PT4070788T
Authority: PT; Portugal
Prior art keywords: pharmaceutical formulations; formulations; pharmaceutical
Prior art date: 2015-06-30

Application number

PT221765373T

Other languages

English (en)

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-30

Filing date

2016-06-29

Publication date

2023-06-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56418608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT4070788(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-06-29 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2023-06-06 Publication of PT4070788T publication Critical patent/PT4070788T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Biophysics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT221765373T 2015-06-30 2016-06-29 Formulações farmacêuticas PT4070788T (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US201562187113P	2015-06-30	2015-06-30
US201662298373P	2016-02-22	2016-02-22
US201662301429P	2016-02-29	2016-02-29
US201662317286P	2016-04-01	2016-04-01

Publications (1)

Publication Number	Publication Date
PT4070788T true PT4070788T (pt)	2023-06-06

Family

ID=56418608

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PT167396258T PT3316868T (pt)	2015-06-30	2016-06-29	Formulações farmacêuticas compreendendo tenofovir e emtricitabina
PT191992577T PT3607939T (pt)	2015-06-30	2016-06-29	Formulações farmacêuticas compreendendo tenofovir e emtricitabina
PT221765373T PT4070788T (pt)	2015-06-30	2016-06-29	Formulações farmacêuticas
PT221765241T PT4070787T (pt)	2015-06-30	2016-06-29	Formulações farmacêuticas

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PT167396258T PT3316868T (pt)	2015-06-30	2016-06-29	Formulações farmacêuticas compreendendo tenofovir e emtricitabina
PT191992577T PT3607939T (pt)	2015-06-30	2016-06-29	Formulações farmacêuticas compreendendo tenofovir e emtricitabina

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT221765241T PT4070787T (pt)	2015-06-30	2016-06-29	Formulações farmacêuticas

Country Status (26)

Country	Link
US (3)	US20180177734A1 (pt)
EP (6)	EP4527467A3 (pt)
JP (3)	JP6667556B2 (pt)
KR (2)	KR102313668B1 (pt)
CN (2)	CN107847450A (pt)
AU (3)	AU2016287500B2 (pt)
BR (1)	BR112017027843A2 (pt)
CA (1)	CA2990210C (pt)
CL (1)	CL2017003320A1 (pt)
CO (1)	CO2017013293A2 (pt)
CU (1)	CU20170168A7 (pt)
DO (1)	DOP2017000306A (pt)
EA (1)	EA201792592A1 (pt)
EC (1)	ECSP17084331A (pt)
ES (5)	ES2945345T3 (pt)
HK (1)	HK1248547A1 (pt)
IL (1)	IL256364A (pt)
MA (1)	MA50541A (pt)
MX (1)	MX2017016806A (pt)
PE (1)	PE20180411A1 (pt)
PH (1)	PH12017502431A1 (pt)
PL (5)	PL3316868T3 (pt)
PT (4)	PT3316868T (pt)
SI (4)	SI3316868T1 (pt)
SV (1)	SV2017005601A (pt)
WO (1)	WO2017004244A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3067358T3 (da)	2012-12-21	2019-11-04	Gilead Sciences Inc	Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
SG11201705069YA (en)	2014-12-26	2017-07-28	Univ Emory	N4-hydroxycytidine and derivatives and anti-viral uses related thereto
BR102016026127A2 (pt)	2015-11-09	2017-05-16	Gilead Sciences Inc	composições terapêuticas para o tratamento do vírus da imunodeficiência humana
NZ797281A (en)	2017-02-17	2025-10-31	Eidos Therapeutics Inc	Processes for preparing ag-10, its intermediates, and salts thereof
WO2018153977A1 (en) *	2017-02-24	2018-08-30	Hexal Ag	Stable composition of tenofovir alafenamide
CA3054822A1 (en) *	2017-03-20	2018-09-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Hiv post-exposure prophylaxis
RU2662160C9 (ru)	2017-07-03	2018-10-22	Александрович Иващенко Андрей	Комбинированный лекарственный препарат для терапии вирусных инфекций
PL3706762T3 (pl)	2017-12-07	2025-02-10	Emory University	N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe
KR20200135996A (ko)	2018-03-23	2020-12-04	에이도스 테라퓨틱스, 인코포레이티드	Ag10을 사용하여 ttr 아밀로이드증을 치료하는 방법
EP4647068A2 (en)	2018-08-17	2025-11-12	Eidos Therapeutics, Inc.	Formulations of ag10
CN111096954B (zh) *	2018-10-29	2022-09-16	江苏豪森药业集团有限公司	一种用于抗病毒感染的药物组合物及制备方法
MA56449A (fr) *	2019-07-03	2022-05-11	Janssen Sciences Ireland Unlimited Co	Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine
CN110251476B (zh) *	2019-08-01	2022-08-09	海思科制药(眉山)有限公司	一种恩曲他滨替诺福韦药物组合物
CN110917197A (zh) *	2019-12-31	2020-03-27	常州恒邦药业有限公司	一种替诺福韦酯与恩曲他滨的药物组合物及其制备方法
TWI728709B (zh) *	2020-02-19	2021-05-21	台灣森本生物科技開發股份有限公司	含有得自於藤黃樹脂的丙酮萃取產物的藥學組成物以及由該組成物所製得的配方
WO2024211882A1 (en) *	2023-04-07	2024-10-10	Navinta, Llc	Stable compositions of rilpivirine hcl in combination with other anti-retroviral agents
CN117338733B (zh) *	2023-10-12	2024-05-28	杭州和泽坤元药业有限公司	一种富马酸替诺福韦二吡呋酯片及其制备工艺
WO2025229473A1 (en) *	2024-05-01	2025-11-06	Lupin Limited	Tenofovir alafenamide compositions
CN119174735A (zh) *	2024-09-03	2024-12-24	安徽贝克生物制药有限公司	一种含利匹韦林的复方片及制备方法
CN119139247A (zh) *	2024-09-05	2024-12-17	安徽贝克生物制药有限公司	一种恩曲他滨丙酚替诺福韦复方片及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2682397B1 (en)	2000-07-21	2017-04-19	Gilead Sciences, Inc.	Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
US20040224917A1 (en)	2003-01-14	2004-11-11	Gilead Sciences, Inc.	Compositions and methods for combination antiviral therapy
TWI471145B (zh) *	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
EA021313B1 (ru)	2009-02-06	2015-05-29	Джилид Сайэнс, Инк.	Таблетки для комбинированной терапии
UA115311C2 (uk)	2011-08-16	2017-10-25	Гіліад Сайєнсіз, Інк.	Геміфумарат тенофовіру алафенаміду
JP6059255B2 (ja) *	2012-02-03	2017-01-11	ギリアードサイエンシスインコーポレーテッド	ウイルス感染の処置における使用のためのテノホビルアラフェンアミドヘミフマル酸塩とコビシスタットを含む併用療法
EP3033084A1 (en) *	2013-08-14	2016-06-22	ratiopharm GmbH	Medicament comprising a pharmaceutical combination of dolutegravir, emtricitabine and tenofovir
CZ2013985A3 (cs) *	2013-12-09	2015-06-17	Zentiva, K.S.	Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
NO2717902T3 (pt) *	2014-06-20	2018-06-23

2016
- 2016-06-29 SI SI201630656T patent/SI3316868T1/sl unknown
- 2016-06-29 JP JP2017566409A patent/JP6667556B2/ja active Active
- 2016-06-29 CU CUP2017000168A patent/CU20170168A7/xx unknown
- 2016-06-29 AU AU2016287500A patent/AU2016287500B2/en active Active
- 2016-06-29 PE PE2017002785A patent/PE20180411A1/es unknown
- 2016-06-29 PT PT167396258T patent/PT3316868T/pt unknown
- 2016-06-29 CA CA2990210A patent/CA2990210C/en active Active
- 2016-06-29 CN CN201680045136.1A patent/CN107847450A/zh active Pending
- 2016-06-29 HK HK18108248.3A patent/HK1248547A1/zh unknown
- 2016-06-29 PL PL16739625T patent/PL3316868T3/pl unknown
- 2016-06-29 KR KR1020207016036A patent/KR102313668B1/ko active Active
- 2016-06-29 EP EP24216441.6A patent/EP4527467A3/en active Pending
- 2016-06-29 BR BR112017027843-0A patent/BR112017027843A2/pt not_active Application Discontinuation
- 2016-06-29 ES ES22176524T patent/ES2945345T3/es active Active
- 2016-06-29 KR KR1020187002382A patent/KR102121329B1/ko active Active
- 2016-06-29 EA EA201792592A patent/EA201792592A1/ru unknown
- 2016-06-29 PL PL19199257.7T patent/PL3607939T3/pl unknown
- 2016-06-29 EP EP19199257.7A patent/EP3607939B1/en active Active
- 2016-06-29 SI SI201631707T patent/SI4070787T1/sl unknown
- 2016-06-29 PL PL22176524.1T patent/PL4070787T3/pl unknown
- 2016-06-29 MX MX2017016806A patent/MX2017016806A/es unknown
- 2016-06-29 MA MA050541A patent/MA50541A/fr unknown
- 2016-06-29 EP EP22176537.3A patent/EP4070788B1/en active Active
- 2016-06-29 SI SI201631702T patent/SI4070788T1/sl unknown
- 2016-06-29 WO PCT/US2016/040158 patent/WO2017004244A1/en not_active Ceased
- 2016-06-29 SI SI201631582T patent/SI3607939T1/sl unknown
- 2016-06-29 US US15/738,067 patent/US20180177734A1/en not_active Abandoned
- 2016-06-29 PT PT191992577T patent/PT3607939T/pt unknown
- 2016-06-29 ES ES22176537T patent/ES2945896T3/es active Active
- 2016-06-29 PT PT221765373T patent/PT4070788T/pt unknown
- 2016-06-29 ES ES23162978T patent/ES3007987T3/es active Active
- 2016-06-29 PL PL22176537.3T patent/PL4070788T3/pl unknown
- 2016-06-29 EP EP23162978.3A patent/EP4233846B1/en active Active
- 2016-06-29 ES ES16739625T patent/ES2786549T3/es active Active
- 2016-06-29 EP EP16739625.8A patent/EP3316868B1/en active Active
- 2016-06-29 PL PL23162978.3T patent/PL4233846T3/pl unknown
- 2016-06-29 PT PT221765241T patent/PT4070787T/pt unknown
- 2016-06-29 CN CN202411894523.5A patent/CN119606990A/zh active Pending
- 2016-06-29 ES ES19199257T patent/ES2925246T3/es active Active
- 2016-06-29 US US15/197,491 patent/US20170000807A1/en not_active Abandoned
- 2016-06-29 EP EP22176524.1A patent/EP4070787B1/en active Active
2017
- 2017-12-17 IL IL256364A patent/IL256364A/en unknown
- 2017-12-21 EC ECIEPI201784331A patent/ECSP17084331A/es unknown
- 2017-12-21 CO CONC2017/0013293A patent/CO2017013293A2/es unknown
- 2017-12-21 CL CL2017003320A patent/CL2017003320A1/es unknown
- 2017-12-21 DO DO2017000306A patent/DOP2017000306A/es unknown
- 2017-12-21 SV SV2017005601A patent/SV2017005601A/es unknown
- 2017-12-22 PH PH12017502431A patent/PH12017502431A1/en unknown
2019
- 2019-07-31 AU AU2019210558A patent/AU2019210558B2/en active Active
2020
- 2020-02-25 JP JP2020029330A patent/JP6978534B2/ja active Active
2021
- 2021-03-31 AU AU2021202009A patent/AU2021202009B2/en active Active
- 2021-09-01 JP JP2021142184A patent/JP2021185188A/ja active Pending
2025
- 2025-02-07 US US19/048,549 patent/US20250281412A1/en active Pending

Also Published As

Publication number	Publication date
PT4070787T (pt)	2023-05-22
MX2017016806A (es)	2018-05-07
EP4527467A3 (en)	2025-05-21
EP3316868B1 (en)	2020-02-19
DOP2017000306A (es)	2018-01-15
EP4233846A2 (en)	2023-08-30
EP3607939B1 (en)	2022-06-01
PL3607939T3 (pl)	2022-11-07
BR112017027843A2 (pt)	2018-09-04
AU2021202009B2 (en)	2023-04-13
US20180177734A1 (en)	2018-06-28
CN119606990A (zh)	2025-03-14
PL4070788T3 (pl)	2023-07-10
JP2018519297A (ja)	2018-07-19
AU2016287500B2 (en)	2019-05-02
ES2925246T3 (es)	2022-10-14
JP2020079304A (ja)	2020-05-28
US20170000807A1 (en)	2017-01-05
PL3316868T3 (pl)	2020-10-19
SI3607939T1 (sl)	2022-10-28
PE20180411A1 (es)	2018-03-01
WO2017004244A1 (en)	2017-01-05
PL4070787T3 (pl)	2023-07-24
JP6667556B2 (ja)	2020-03-18
EP3316868A1 (en)	2018-05-09
PH12017502431A1 (en)	2018-07-02
KR102121329B1 (ko)	2020-06-17
KR20180021134A (ko)	2018-02-28
EA201792592A1 (ru)	2018-06-29
JP2021185188A (ja)	2021-12-09
CN107847450A (zh)	2018-03-27
KR20200067937A (ko)	2020-06-12
CA2990210C (en)	2021-01-12
EP4070788B1 (en)	2023-03-22
EP4233846A3 (en)	2023-10-04
CA2990210A1 (en)	2017-01-05
MA50541A (fr)	2021-04-07
ES2945896T3 (es)	2023-07-10
SI3316868T1 (sl)	2020-04-30
US20250281412A1 (en)	2025-09-11
PL4233846T3 (pl)	2025-03-24
SI4070788T1 (sl)	2023-06-30
EP3607939A1 (en)	2020-02-12
SI4070787T1 (sl)	2023-07-31
SV2017005601A (es)	2018-05-04
EP4233846B1 (en)	2024-12-04
EP4527467A2 (en)	2025-03-26
EP4070787B1 (en)	2023-03-01
ES2945345T3 (es)	2023-06-30
IL256364A (en)	2018-02-28
CL2017003320A1 (es)	2018-07-13
ECSP17084331A (es)	2018-01-31
PT3607939T (pt)	2022-09-12
PT3316868T (pt)	2020-04-21
JP6978534B2 (ja)	2021-12-08
KR102313668B1 (ko)	2021-10-19
CU20170168A7 (es)	2018-07-05
EP4070788A1 (en)	2022-10-12
AU2016287500A1 (en)	2018-01-18
HK1248547A1 (zh)	2018-10-19
EP4070787A1 (en)	2022-10-12
CO2017013293A2 (es)	2018-05-31
EP4233846C0 (en)	2024-12-04
ES2786549T3 (es)	2020-10-13
AU2021202009A1 (en)	2021-04-29
AU2019210558A1 (en)	2019-08-15
AU2019210558B2 (en)	2021-04-22
ES3007987T3 (en)	2025-03-21

Publication	Publication Date	Title
PT4070788T (pt)	2023-06-06	Formulações farmacêuticas
EP3513809A4 (en)	2020-06-03	MEDICAL COMPOSITION
DK3529248T3 (da)	2020-09-14	Farmaceutiske sammensætninger
DK3089741T3 (da)	2021-06-07	Farmaceutiske sammensætninger omfattende azd9291
IL256491A (en)	2018-02-28	Pharmaceutical formulations
DK3199161T3 (da)	2022-01-03	Farmaceutisk præparat
EP3364945C0 (en)	2024-12-04	SOLID FORMULATION
DK3634377T3 (da)	2021-08-30	Farmaceutisk formulering
EP3603642A4 (en)	2020-09-02	PHARMACEUTICAL PREPARATION
DK3463345T3 (da)	2023-01-09	Farmaceutiske kombinationer
EP3454847A4 (en)	2019-12-18	IMPROVED DRUG FORMULATIONS
IL254794A0 (en)	2017-12-31	Pharmaceutical formulations
EP3383371C0 (en)	2024-05-01	PHARMACEUTICAL FORMULATION
EP3646866A4 (en)	2021-03-24	PHARMACEUTICAL PREPARATION
EP3337463A4 (en)	2019-04-03	PHARMACEUTICAL FORMULATIONS
DK3313370T3 (da)	2021-03-29	Oftalmologisk farmaceutisk sammensætning
HUE069648T2 (hu)	2025-03-28	Gyógyszerészeti készítmény
DK3601277T3 (da)	2024-01-15	Farmaceutisk formulering
EP3395344A4 (en)	2019-09-04	MEDICINE
HUE050881T2 (hu)	2021-01-28	Gyógyszerkészítmény
EP3441073A4 (en)	2019-04-17	MEDICAL COMPOSITION
DK3288967T3 (da)	2020-02-10	Farmaceutisk forbindelse
TR201503831A2 (tr)	2016-10-21	Antimipertansif kombinasyon formülasyonları
EP3563847A4 (en)	2019-12-25	PHARMACEUTICAL COMPOSITION
EP3563845A4 (en)	2019-12-25	PHARMACEUTICAL COMPOSITION